Chemotherapy of Burkitt's lymphoma

J. Ziegler
DOI: https://doi.org/10.1002/1097-0142(197212)30:6<1534::AID-CNCR2820300619>3.0.CO;2-6
IF: 6.9209
1972-12-01
Cancer
Abstract:Results of treatment of 117 patients with Burkitt's lymphoma followed for a minimum of 18 months were analyzed. All patients were clinically staged and treated according to randomized clinical trials. Sixteen patients (14%) died within the first week of treatment of causes related to widespread tumor. Ninety‐five of the remaining 101 evaluable patients achieved complete remission (95%), while six had partial responses and eventually died. The frequency of relapse was significantly lower in patients with localized tumors (39%) as compared to patients with generalized disease (70%), but was unaffected by the intensity of the initial therapeutic regimen. Patients who developed early relapse (within 10 weeks of first treatment) had a less favorable prognosis than patients who relapsed beyond this period. Preliminary results of a current immunotherapeutic trial using BCG following cyclophosphamide‐induced remission suggest a protective effect of this treatment on the development of extradural relapse. These results provide guidelines for future therapeutic approaches which are discussed.
What problem does this paper attempt to address?